Changes in Breast Cancer Screening Prevalence in the United States during the COVID-19 Pandemic, 2018 to 2022.

IF 3.7 3区医学 Q2 ONCOLOGY

Cancer Epidemiology Biomarkers & Prevention Pub Date : 2025-01-09 DOI:10.1158/1055-9965.EPI-24-0540

Kilan C Ashad-Bishop, Jessica Star, Angela N Giaquinto, Robert A Smith, Ahmedin Jemal, Priti Bandi

{"title":"Changes in Breast Cancer Screening Prevalence in the United States during the COVID-19 Pandemic, 2018 to 2022.","authors":"Kilan C Ashad-Bishop, Jessica Star, Angela N Giaquinto, Robert A Smith, Ahmedin Jemal, Priti Bandi","doi":"10.1158/1055-9965.EPI-24-0540","DOIUrl":null,"url":null,"abstract":"Background: Annual mammography screening declined year-on-year during the COVID-19 pandemic through 2021. This study examined changes in 2022 compared with 2018 in the national prevalence of self-reported up-to-date mammography.Methods: Using 2018 to 2022 data from the Center for Disease Control and Prevention's Behavioral Risk Factor Surveillance System, we assess relative changes defined as annual prevalence ratios (aPR) in the SR receipt of past-year and up-to-date (UTD) breast cancer screening (biannual mammography in women of ages 50-74 years) during the third year of the COVID-19 pandemic overall and by sociodemographic characteristics.Results: UTD breast cancer screening declined for the first time since 2018 [2018 compared with 2022, from 78.7%-76.6%; aPR, 0.97; 95% confidence interval (CI), 0.96-0.98] despite a small increase in past-year breast cancer screening from 2020 to 2022 (57.9%-59.6%; aPR, 1.03; 95% CI, 1.01-1.05). This translated to 747,791 fewer women reporting UTD with recommended breast cancer screening in 2022 versus 2018. UTD breast cancer screening declines between 2018 and 2022 were largest for American Indian/Alaska Native women (74.8%-62.2%; aPR, 0.83; 95% CI, 0.74-0.93), women with less formal educational attainment (< high school: 73.1%-65.5%; aPR, 0.9; 95% CI, 0.85-0.95), and women without a usual source of care (48%-42.9%; aPR, 0.85; 95% CI, 0.78-0.92).Conclusions: Previously noted pandemic-related declines in past-year breast cancer screening now reflect in women reporting being UTD, with the largest declines in American Indian/Alaska Native women and those with lower socioeconomic status.Impact: Future studies should monitor screening prevalence in relation to breast cancer diagnostic stage overall and by sociodemographic groups.","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"133-138"},"PeriodicalIF":3.7000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-24-0540","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Annual mammography screening declined year-on-year during the COVID-19 pandemic through 2021. This study examined changes in 2022 compared with 2018 in the national prevalence of self-reported up-to-date mammography.

Methods: Using 2018 to 2022 data from the Center for Disease Control and Prevention's Behavioral Risk Factor Surveillance System, we assess relative changes defined as annual prevalence ratios (aPR) in the SR receipt of past-year and up-to-date (UTD) breast cancer screening (biannual mammography in women of ages 50-74 years) during the third year of the COVID-19 pandemic overall and by sociodemographic characteristics.

Results: UTD breast cancer screening declined for the first time since 2018 [2018 compared with 2022, from 78.7%-76.6%; aPR, 0.97; 95% confidence interval (CI), 0.96-0.98] despite a small increase in past-year breast cancer screening from 2020 to 2022 (57.9%-59.6%; aPR, 1.03; 95% CI, 1.01-1.05). This translated to 747,791 fewer women reporting UTD with recommended breast cancer screening in 2022 versus 2018. UTD breast cancer screening declines between 2018 and 2022 were largest for American Indian/Alaska Native women (74.8%-62.2%; aPR, 0.83; 95% CI, 0.74-0.93), women with less formal educational attainment (< high school: 73.1%-65.5%; aPR, 0.9; 95% CI, 0.85-0.95), and women without a usual source of care (48%-42.9%; aPR, 0.85; 95% CI, 0.78-0.92).

Conclusions: Previously noted pandemic-related declines in past-year breast cancer screening now reflect in women reporting being UTD, with the largest declines in American Indian/Alaska Native women and those with lower socioeconomic status.

Impact: Future studies should monitor screening prevalence in relation to breast cancer diagnostic stage overall and by sociodemographic groups.

查看原文本刊更多论文

2018-2022 年 COVID-19 大流行期间美国乳腺癌筛查流行率的变化。

背景：在COVID-19大流行期间至2021年，乳腺X线照相术年筛查率逐年下降。本研究考察了 2022 年与 2018 年相比，全国自我报告的最新乳腺放射摄影流行率的变化情况：利用疾病控制和预防中心（CDC）行为风险因素监测系统（BRFSS）提供的2018-2022年数据，我们评估了COVID-19大流行第三年期间SR接受过去一年和最新（UTD）乳腺癌筛查（50-74岁女性一年两次乳房X线照相术）的相对变化（定义为年流行率比（aPR））：自2018年以来，UTD BC筛查率首次下降（2018年与2022年相比，从78.7%降至76.6%；aPR，0.97；95% CI，0.96-0.98），尽管从2020年到2022年，上一年的乳腺癌筛查率略有增加（57.9%增至59.6%；aPR，1.03；95% CI，1.01-1.05）。这意味着 2022 年与 2018 年相比，报告UTD 接受建议 BC 筛查的女性人数减少了 747 791 人。2018-2022年期间，美国印第安人/阿拉斯加原住民妇女（74.8%降至62.2%；aPR，0.83；95% CI，0.74-0.93）、正规教育程度较低的妇女（<高中：73.1%降至65.5%；aPR，0.9；95% CI，0.85-0.95）和没有惯常护理来源的妇女（48%降至42.9%；aPR，0.85；95% CI，0.78-0.92）的UTD BC筛查下降幅度最大：结论：之前注意到的与大流行相关的上一年 BC 筛查率的下降现在反映在报告未接受筛查的女性中，其中下降幅度最大的是亚裔美国人/印第安人和社会经济地位较低的女性：影响：未来的研究应监测筛查流行率与 BC 诊断阶段的关系，包括总体流行率和社会人口群体流行率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Epidemiology Biomarkers & Prevention 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.50

自引率

2.60%

发文量

538

审稿时长

1.6 months

期刊介绍： Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.